Trial Profile
Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Tandospirone (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Acronyms TACGAD
- Sponsors Sumitomo Dainippon Pharma; Sumitomo Pharma
- 01 Apr 2023 Results of post hoc analysis assessing arly outcomes, associated factors and predictive values of clinical outcomes of different tandospirone doses in patients with a generalized anxiety disorder published in the Current Medical Research and Opinion
- 05 Jan 2020 Status changed from recruiting to completed.
- 15 Apr 2019 Planned End Date changed from 1 Dec 2017 to 1 Jul 2019.